Anti-Neutrophil Cytoplasmic Autoantibody-Associated Vasculitides

Dear Colleagues,

Anti-neutrophil cytoplasmic autoantibodies (ANCA)-associated vasculitides are characterized by the presence of ANCA in the circulation and a paucity of staining for immunoglobulins by histopathology. Genetic distinctions and discrete clinical syndromes or disease profiles have been associated with the type of ANCA. ANCA-associated vasculitides may occur as a renal-limited disease or as a component of systemic necrotizing small-vessel vasculitis. ANCA glomerulonephritis is the most common cause of crescentic glomerulonephritis, which often follows a course of rapid progression to end stage renal disease if left untreated. Speed in diagnosis of ANCA-associated vasculitis is the most crucial matter for these patients. Aggressive immunosuppressive therapy is justified by poor patient and renal survival rates in untreated patients. However, toxicity related to therapy is still remarkable and thus, continuing efforts are aiming to improve treatment options in order to minimize it.

This Special Issue intends to provide the reader with a comprehensive overview of the current insights into the pathogenesis and management of ANCA-associated vasculitides, focusing on important evidence-based developments in this critical field.

Dr. Sophia Lionaki
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibodies is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• Epidemiology
• Pathogenesis
• The role of ANCA in pathogenesis
• Initial immunosuppressive therapy
• Maintenance therapy
• Management of persistent, refractory, or relapsing disease
• Prognosis; Predictors of patient and renal Survival
• Renal replacement modalities